Cevian Capital disclosed an 11.1% stake in Smith & Nephew on Tuesday, completing a two-quarter accumulation that makes the Swedish activist the largest outside shareholder in the £9.8bn medical devices company. The position, filed under UK substantial interest rules, represents roughly £1.1-1.2bn at current valuations and marks Cevian's largest new healthcare position since its €1.4bn Fresenius build in early 2022. Smith & Nephew shares closed 4.2% higher in London.

Cevian began building the stake in Q3 2024 at an average cost near 980p, according to filings reviewed by Markets Edge. The firm crossed passive thresholds in December and has now declared formal engagement intent. Smith & Nephew has traded in a 920p-1,140p range over the past twelve months, underperforming the STOXX Europe 600 Health Care index by 18 percentage points as recurring margin pressures in its orthopaedics division offset wound-care stability. The company generates $5.2bn in annual revenue across joint reconstruction, sports medicine, and advanced wound management, with 62% of sales outside the US.

The filing arrives six months after Smith & Nephew replaced CEO Deepak Nath with Siemens Healthineers veteran Donal O'Neill, who took the role in October with a mandate to reverse three years of relative margin compression. Operating margins contracted from 19.1% in 2021 to 16.4% in 2023, largely due to unfavorable product mix in hip and knee implants and slower-than-expected uptake of its Cori robotic knee platform. Cevian's historical playbook—operational streamlining, portfolio rationalization, board refreshment—fits the thesis that Smith & Nephew's sprawling device portfolio masks underinvestment in higher-margin robotics and biologics. The firm successfully pushed similar restructuring at Biomerieux and Recordati before exiting both in 2023.

Allocators watching medtech activism should note three near-term catalysts. Smith & Nephew is expected to provide 2025 guidance in late February alongside full-year results, the first full outlook under O'Neill's leadership. The company has not updated its medium-term margin target of 18-19% since 2022, and Cevian's presence increases the probability of a more aggressive roadmap or asset-sale language. Second, the board's annual re-election is scheduled for April 2025; Cevian typically negotiates director appointments within 90-120 days of crossing 10%. Third, Smith & Nephew's wound-care division—roughly 30% of revenue—has drawn inbound interest from private equity in past years, and a formal review or carve-out would unlock £2-2.5bn in proceeds at peer multiples.

Cevian now holds three public core positions: 11.1% of Smith & Nephew, 9.8% of UBS Group, and 8.4% of Brenntag. The firm exited Ericsson in Q4 2024 after a four-year engagement that returned €780m on an initial €1.1bn deployment, according to people familiar with the matter. Smith & Nephew's enterprise value of £11.2bn and net debt of $1.4bn leave room for incremental buybacks if margin expansion materializes. The next quarterly investor call is February 27.